hotspot -WSS

hotspot

author：leisure time 2025-09-30 16:27:49 - browse：74897

CHICAGO — A next-generation CAR-T therapy was able to substantially shrink tumors in patients with liver cancer in early clinical data presented Monday at the American Society of Clinical Oncology annual meeting. The study, though preliminary and small with only 24 patients, represents a triad of firsts for one of the trial’s sponsors.

“It’s the first CAR therapy working in liver cancer. First validation of targeting GPC3 as a target. It’s the first validation of our armoring strategy. And it’s the first of many of our visions of CAR therapy in general,” Matt Hellmann, a medical oncologist and early development oncology lead at AstraZeneca, said in an interview.

This abstract, presented by cancer researcher Qi Zhang of Zhejiang University School of Medicine, is yet another significant showing by AstraZeneca at this ASCO. The company had two plenary presentations on its blockbuster lung cancer drug Tagrisso and immunotherapy drug Imfinzi — as well as new results on Enhertu, which AstraZeneca developed with Daiichi Sankyo.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Bernie Sanders bashes nonprofit hospitals over their tax breaks

explore

WSS

Medicare details structure of new drug price negotiation program

Hepatitis C has a cure — but many Americans still lack access to it

Moonlake's readout produced a cash windfall. Risks remain

Jerome Adams on the need for new antivirals for Covid

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Hepatitis C has a cure — but many Americans still lack access to it

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medical leaders decry Supreme Court decision on affirmative action

A revolution in caring for preterm infants

Psychedelics group wrestles with new pharma identity

How doctors and nurses shape Google's AI

Hepatitis C has a cure — but many Americans still lack access to it

The high cost of giving birth even with insurance

United colonoscopy coverage change 'may cost lives,' doctors say

Apple is now the first public company to be valued at $3 trillion

Medicare details structure of new drug price negotiation program

Drug repurposing or repositioning? The language matters

entertainment

How clinical AI models' predictive power can degrade over time

In Memoriam: Notable people who died in 2023

Medical leaders decry Supreme Court decision on affirmative action

STAT Readout: Today's biotech news includes Sana and Amylyx

A revolution in caring for preterm infants

Humana CEO Bruce Broussard to step down in 2024

explore

focus

explore

entertainment